Table 1.
Main characteristics of the included studies
| Author | Year | Gender | Age (y) | Type | Experiment | Events (n) | Control | Events (n) | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| John Pippen | 2006 | F: 197 (100%) | 51.2±9.23 | RCT | AC-albumin-bound paclitaxel + bevacizumab | 28/98 | AC-paclitaxel + bevacizumab | 22/99 | AEs |
| William J. Gradishar | 2006 | F: 150 (100%) | 53.9±10.05 | RCT | Nab-paclitaxel | 5/76 | Docetaxel | 4/74 | ORR |
| NCT00540514 | 2007 | F: 263 (25%) | 59.6±9.33 | RCT | albumin-bound paclitaxel + Carboplatin | 50/514 | paclitaxel + Carboplatin | 43/524 | ORR |
| M: 789 (75%) | |||||||||
| NCT02033993 | 2014 | F: 55 (27.6%) | 67 (24-88) | RCT | Nab-paclitaxel + Platinum | 15/99 | Paclitaxel + Platinum | 20/100 | PFS |
| M: 144 (72.4%) | |||||||||
| NCT02367794 | 2015 | F: 186 (18.2%) | 64.6 (8.6) | RCT | Atezolizumab + Nab-paclitaxel + Carboplatin | 48/334 | Tezolizumab + paclitaxel + Carboplatin | 54/332 | PFS/OS |
| M: 835 (81.8%) | |||||||||
| NCT00785291 | 2008 | F: 788 (98.6%) | NR | RCT | Nab-paclitaxel + bevacizumab | 85/264 | paclitaxel + bevacizumab | 31/272 | PFS |
| M: 11 (1.4%) | |||||||||
| Liang Huang | 2015 | F: 120 (100%) | 49 (29-66) | RCT | Nab-paclitaxel + Carboplatin | 11/30 | Paclitaxel + Carboplatin | 23/90 | pCR |
| Kenji Tamaura | 2017 | F: 200 (100%) | NR | RCT | Nab-paclitaxel | 61/100 | paclitaxel | 50/100 | PFS |
| Zhong-Zhen GUAN | 2009 | F: 210 (100%) | 50 (24-70) | RCT | Nab-paclitaxel | 28/104 | paclitaxel | 10/106 | ORR |
| Kohei Shitara | 2017 | F: 129 (27.0%) | NR | RCT | Nab-paclitaxel | 22/241 | paclitaxel | 16/243 | OS |
| M: 354 (73.0%) | |||||||||
| Michael Untch | 2016 | F: 1206 (100%) | NR | RCT | Nab-paclitaxel-AC/HP | 202/605 | paclitaxel-AC/HP | 143/601 | pCR |
Note: F = female; M = male; NR = not report; RCT: randomized controlled trial; A: epirubicin; C: cyclophosphamide; H: trastuzumab; P: pertuzumab; AEs: adverse events; ORR: overall response rate; PFS: progression-free survival; OS: overall survival; pCR: pathologic complete response.